USPTO 2015–2025 USPTO PatentsView Foreign Corporation

UCB Biopharma SRL

USPTO PatentsView assignee record - 251 granted patents across 34 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

251

Total patents granted

CPC technology areas

15.7

Avg claims per patent

+9%

5-year filing velocity

The verdict

UCB holds 251 US patents across 34 technology areas, rank #1,643 of 50,000 tracked assignees.

#1,643
of 50,000 US assignees by volume: Top 9%
by Innovation Score (53.7/100): 15.7
avg claims per patent: +9%
filing velocity, last 5 yrs

Portfolio overview

UCB Biopharma SRL has been granted 251 US utility patents between 2015 and 2025, placing UCB Biopharma SRL at rank #1,643 across all assignees tracked by PlainPatent. This portfolio spans 34 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, UCB Biopharma SRL is one of the more focused assignees in the PatentsView dataset. By volume, UCB sits between Datalogic IP Tech S.r.l. (251 patents, rank #1,639) and Valinge Innovation AB (250 patents, rank #1,647) - the closest US assignees by grant volume. The composite Innovation Score of 53.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 131 grants, compared with 120 in the 2015–2019 window, a +9% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. UCB Biopharma SRL's 15.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 34 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark UCB Biopharma SRL against peers pursuing similar technology classes.

Datalogic IP Tech…

251
GD Midea Air-cond…

251
Guardian Glass

251
THE Aerospace

251
Zscaler

251
UCB Biopharma SRL ◀

251
American AXLE & M…

250
Smith Internation…

250
Valinge Innovatio…

250

What this shows UCB holds 251 patents at rank #1,643, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near UCB

By rank, the assignees closest to #1,643 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in UCB's primary technology class.

UCB's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

54 Top 9% higher than 91% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

UCB Biopharma SRL patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	1.6%
2016	13	5.2%
2017	21	8.4%
2018	48	19.1%
2019	34	13.5%
2020	27	10.8%
2021	30	12.0%
2022	32	12.7%
2023	11	4.4%
2024	19	7.6%
2025	12	4.8%

Which technologies does UCB Biopharma SRL patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 157

C07K - PEPTIDES 123

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 122

C07D - HETEROCYCLIC COMPOUNDS 80

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 27

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 25

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 10

F04C - ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS ; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS 9

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 9

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 9

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 6

B01D - SEPARATION 4

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 4

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 4

G06F - ELECTRIC DIGITAL DATA PROCESSING 4

Top 15 of 34 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#1,643

Across all tracked assignees

Innovation Score

53.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does UCB Biopharma SRL hold?

UCB Biopharma SRL holds 251 US granted patents filed between 2015 and 2025, spanning 34 technology areas.

What is UCB Biopharma SRL's Innovation Score?

UCB Biopharma SRL has an Innovation Score of 53.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does UCB Biopharma SRL focus on?

UCB Biopharma SRL's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 157 patents. The company has filed patents in 34 CPC subclasses total.

Is UCB Biopharma SRL's patent filing rate increasing or decreasing?

UCB Biopharma SRL's recent filing velocity is +9% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for UCB Biopharma SRL's patents?

UCB Biopharma SRL's patents average 15.7 claims each. This falls within the standard range, providing solid legal coverage.

How is the UCB Biopharma SRL patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

UCB's 251 grants land it in the top 9% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - UCB ranks #1,643 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.